CD274 and hepatocellular carcinoma: Intriguingly, a high CAGS predicted poor OS prognosis in HCC patients but exhibited a clinical advantage in anti‐PD‐1/PD‐L1 immunotherapy, with a higher response rate in comparison with the low CAGS group (response/nonresponse = 48.33%/51.67%).